Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
-
Radiat Oncol J. 2017 Jun;35(2):137-143. English. Original Article. https://doi.org/10.3857/roj.2017.02026
Weiner JP , Schwartz D , Shao M , Osborn V , Choi K , Schreiber D .
Department of Radiation Oncology, Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY, USA. joseph.p.weiner@gmail.com
Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA.
Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
Abstract

PURPOSE: To analyze the utilization and fractionation of extreme hypofractionation via stereotactic body radiotherapy (SBRT) in the treatment of prostate cancer. MATERIALS AND METHODS: Data was analyzed on men diagnosed with localized prostate cancer between 2004–2012 and treated with definitive-intent radiation therapy, as captured in the National Cancer Database. This database is a hospital-based registry that collects an estimated 70% of all diagnosed malignancies in the United States. RESULTS: There were 299,186 patients identified, of which 4,962 (1.7%) were identified as receiving SBRT as primary treatment. Of those men, 2,082 had low risk disease (42.0%), 2,201 had intermediate risk disease (44.4%), and 679 had high risk disease (13.7%). The relative utilization of SBRT increased from 0.1% in 2004 to 4.0% in 2012. Initially SBRT was more commonly used in academic programs, though as time progressed there was a shift to favor an increased absolute number of men treated in the community setting. Delivery of five separate treatments was the most commonly utilized fractionation pattern, with 4,635 patients (91.3%) receiving this number of treatments. The most common dosing pattern was 725 cGy × 5 fractions (49.6%) followed by 700 cGy × 5 fractions (21.3%). CONCLUSIONS: Extreme hypofractionation via SBRT is slowly increasing acceptance. Currently 700-725 cGy × 5 fractions appears to be the most commonly employed scheme. As further long-term data regarding the safety and efficacy emerges, the relative utilization of this modality is expected to continue to increase.

Copyright © 2019. Korean Association of Medical Journal Editors.